Faculty Bibliography

Background: Hemodialysis (HD) can reduce amyloid-beta (Abeta) species in wholebody circulation by 30 to 50%. Due to the dynamic exchange of Abeta between the brain and the blood, we hypothesized that HD might lower Abeta levels in the cerebrospinal fluid (CSF).
Method(s): In a dialysis network with over 160,000 patients, we identified three maintenance HD patients (age 36+/-9 years) with ventriculo-peritoneal (VP) shunts who were subsequently recruited for this IRB-approved research study. Study subjects were dialyzed on Monday, Wednesday, and Friday. Plasma samples were collected at 6 timepoints during the 3 HD sessions. One subject was withdrawn over safety concern related to the VP shunt tap procedure. Two subjects further underwent VP shunt taps for CSF sample collection before and after the Wednesday and Friday HD sessions, and once on interdialytic days (Tuesday, Thursday). Abeta1-42 and Abeta1-40 were quantified by Neuro 3-Plex SIMOA assays (Quanterix, MA, USA).
Result(s): HD effectively reduced plasma Abeta1-40 by 41% and Abeta1-42 by 34% (Fig 1a and 1b, p < 0.01). In CSF, levels of Abeta increased after Wednesday HD sessions in subject 1 (Abeta1-40: 4.2-fold, Abeta1-42: 5.5-fold) and subject 2 (Abeta1-40 and Abeta1-42: 1.06-fold), while Abeta decreased after Friday HD sessions in both subject 1 (Abeta1-40: 0.1-fold, Abeta1-42: 0.1-fold) and 2 (Abeta1-40: 0.7-fold, Abeta1-42: 0.7-fold) shown in Figure 1c-f.
Conclusion(s): This is the first report of Abeta dynamics in the CSF and plasma of HD patients. While plasma levels were in similar ranges, we found high inter-individual variations of CSF levels. Different plasma-to-CSF ratios after HD may reflect individual brain Abeta pools that are accessed by HD. We corroborate previous reports demonstrating the removal of Abeta from the blood compartment by HD. (Figure Presented)

BACKGROUND:The coronavirus disease 2019 (COVID-19) is a systemic entity that frequently implies neurologic features at presentation and complications during the disease course. We aimed to describe the characteristics and predictors for developing in-hospital neurologic manifestations in a large cohort of hospitalized patients with COVID-19 in Mexico City. METHODS:We analyzed records from consecutive adult patients hospitalized from March 15 to June 30, 2020, with moderate to severe COVID-19 confirmed by reverse transcription real-time polymerase chain reaction (rtRT-PCR) for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Neurologic syndromes were actively searched by a standardized structured questionnaire and physical examination, confirmed by neuroimaging, neurophysiology of laboratory analyses, as applicable. RESULTS:We studied 1,072 cases (65% men, mean age 53.2±13 years), 71 patients had pre-existing neurologic diseases (diabetic neuropathy: 17, epilepsy: 15, history of ischemic stroke: eight, migraine: six, multiple sclerosis: one, Parkinson disease: one), and 163 (15.2%) developed a new neurologic complication. Headache (41.7%), myalgia (38.5%), dysgeusia (8%), and anosmia (7%) were the most common neurologic symptoms at hospital presentation. Delirium (13.1%), objective limb weakness (5.1%), and delayed recovery of mental status after sedation withdrawal (2.5%), were the most common new neurologic syndromes. Age, headache at presentation, preexisting neurologic disease, invasive mechanical ventilation, and neutrophil/lymphocyte ratio ≥9 were independent predictors of new in-hospital neurologic complications. CONCLUSIONS:Even after excluding initial clinical features and pre-existing comorbidities, new neurologic complications in hospitalized patients with COVID-19 are frequent and can be predicted from clinical information at hospital admission.

The objective is to quantitatively assess surgical outcomes in epilepsy patients who underwent scanning at 7T MRI whose lesions were undetectable at conventional field strengths (1.5T/3T). 16 patients who underwent an initial 1.5T/3T scan that was marked as non-lesional by a neuroradiologist and were candidates for epilepsy surgery were scanned at 7T. The 7T findings were evaluated by an expert neuroradiologist blinded to the suspected seizure onset zone (sSOZ). The relation of the neuroradiologist's findings compared with the sSOZ was classified as non-definite (no 7T lesion or lesion of no epileptogenic significance, or lesion of epileptogenic potential which localizes to the patient's sSOZ but is not the definitive cause), or definite (7T lesion of epileptogenic potential that highly localizes to the sSOZ and is confirmed through surgical intervention).. Each patient underwent neurosurgical intervention and postoperative Engel outcomes were obtained through retrospective chart review by an epileptologist. Of the 16 patients, 7 had imaging findings of definite epileptogenic potential at 7T while 9 had non-definite imaging findings. 15 out of 16 patients had Engel I, II, or III outcomes indicating worthwhile improvement. Patients with definite lesion status achieved Engel I surgical outcomes at higher rates (57.1%) than patients with non-definite lesion status (33.3%). Patients with normal clinical diagnostic scans at lower field strengths who have definite radiological findings on 7T corresponding to the sSOZ may experience worthwhile improvement from surgical intervention.

Introduction: Quantifying upper extremity (UE) motor impairment after stroke is impractical, limiting our ability to tailor rehabilitation training in real time. The current gold-standard measure of impairment, the Fugl-Meyer Assessment (FMA), is time-consuming and requires a trained assessor. The FMA furthermore does not assess functional motions in real-world contexts, which is exactly where we aim our rehabilitation interventions. Here, we took initial steps to develop an approach to automatically quantify UE motor impairment during functional task performance.
Method(s): We studied 51 chronic stroke patients (28F:23M; 57.7 (21.3-84.3) years old; 28L:23R paretic; FMA 43.1 (8-65)).We recorded upper body motion with 9 inertial measurement units (IMUs) while patients performed the FMA and a functional task (moving an object on a horizontal 8-target array). We trained a long short-term memory (LSTM) deep learning model to estimate FMA scores from the recorded motion (training set n=40; test set n=11; 4 LSTM layers with between-layer batch normalization; IMU data windows of 4s with slide of 1s). LSTM-generated impairment scores were computed from FMA motions or from functional motions. To ascertain the accuracy of the approach, we calculated the root mean square error (RMSE) and the Spearman correlation coefficient (rho) between the LSTM scores and the FMA scores from a trained expert. We also examined whether the performance of particular classes of functional primitives (i.e. reach, transport, or reposition) would be sufficient to accurately estimate impairment.
Result(s): Using motions from the FMA performance, our approach estimated FMA scores within 1.1 points of a trained assessor. Using motions from the functional task performance, our approach estimated FMA scores within 1.6 points. Correlation values between the FMA scores and LSTM scores were rho = 0.98 for FMA motions and rho = 0.96 for functional motions. Among the three functional primitives, reaches were the most informative for estimating the impairment scores (RMSE: 1.9 points), followed by transports (RMSE: 2.1 points), and repositions (RMSE: 2.8 points).
Discussion(s): We present a new approach that uses sensor-based motion capture and deep learning to automatically estimate UE motor impairment. This approach has high accuracy and shows high concurrent validity with the FMA, even when it assesses unrelated functional motions. Thus, it may be possible to directly measure impairment from performance of real-world functional tasks, which the FMA does not offer. Estimating impairment during stroke rehabilitation would enable clinicians to tailor treatment strategy in real time.

Sudden unexpected death in epilepsy is the leading category of epilepsy-related death and the underlying mechanisms are incompletely understood. Risk factors can include a recent history and high frequency of generalized tonic-clonic seizures, which can depress brain activity postictally, impairing respiration, arousal and protective reflexes. Neuropathological findings in sudden unexpected death in epilepsy cases parallel those in other epilepsy patients, with no implication of novel structures or mechanisms in seizure-related deaths. Few large studies have comprehensively reviewed whole brain examination of such patients. We evaluated 92 North American Sudden unexpected death in epilepsy Registry cases with whole brain neuropathological examination by board-certified neuropathologists blinded to the adjudicated cause of death, with an average of 16 brain regions examined per case. The 92 cases included 61 sudden unexpected death in epilepsy (40 definite, 9 definite plus, 6 probable, 6 possible) and 31 people with epilepsy controls who died from other causes. The mean age at death was 34.4 years and 65.2% (60/92) were male. The average age of death was younger for sudden unexpected death in epilepsy cases than for epilepsy controls (30.0 versus 39.6 years; P = 0.006), and there was no difference in sex distribution respectively (67.3% male versus 64.5%, P = 0.8). Among sudden unexpected death in epilepsy cases, earlier age of epilepsy onset positively correlated with a younger age at death (P = 0.0005) and negatively correlated with epilepsy duration (P = 0.001). Neuropathological findings were identified in 83.7% of the cases in our cohort. The most common findings were dentate gyrus dysgenesis (sudden unexpected death in epilepsy 50.9%, epilepsy controls 54.8%) and focal cortical dysplasia (FCD) (sudden unexpected death in epilepsy 41.8%, epilepsy controls 29.0%). The neuropathological findings in sudden unexpected death in epilepsy paralleled those in epilepsy controls, including the frequency of total neuropathological findings as well as the specific findings in the dentate gyrus, findings pertaining to neurodevelopment (e.g. FCD, heterotopias) and findings in the brainstem (e.g. medullary arcuate or olivary dysgenesis). Thus, like prior studies, we found no neuropathological findings that were more common in sudden unexpected death in epilepsy cases. Future neuropathological studies evaluating larger sudden unexpected death in epilepsy and control cohorts would benefit from inclusion of different epilepsy syndromes with detailed phenotypic information, consensus among pathologists particularly for more subjective findings where observations can be inconsistent, and molecular approaches to identify markers of sudden unexpected death in epilepsy risk or pathogenesis.

Background: Deep brain stimulation of the subthalamic nucleus (STN-DBS) is an effective treatment for Parkinson's disease (PD) but can have an adverse effect on speech. In normal speakers and in those with spinocerebellar ataxia, an inverse relationship between regional cerebral blood flow (rCBF) in the left inferior frontal (IFG) region and the right caudate (CAU) is associated with speech rate. This pattern was examined to determine if it was present in PD, and if so, whether it was altered by STN-DBS. Methods: Positron Emission Tomography (PET) measured rCBF during speech in individuals with PD not treated with STN-DBS (n = 7), and those treated with bilateral STN-DBS (n = 7). Previously reported results from non-PD control subjects (n = 16) were reported for comparison. The possible relationships between speech rate during scanning and data from the left and right IFG and CAU head regions were investigated using a step-wise multiple linear regression to identify brain regions that interacted to predict speech rate. Results: The multiple linear regression analysis replicated previously reported predictive coefficients for speech rate involving the left IFG and right CAU regions. However, the relationships between these predictive coefficients and speech rates were abnormal in both PD groups. In PD who had not received STN-DBS, the right CAU coefficient decreased normally with increasing speech rate but the left IFG coefficient abnormally decreased. With STN-DBS, this pattern was partially normalized with the addition of a left IFG coefficient that increased with speech rate, as in normal controls, but the abnormal left IFG decreasing coefficient observed in PD remained. The magnitudes of both cortical predictive coefficients but not the CAU coefficient were exaggerated with STN-DBS. Conclusions: STN-DBS partially corrects the abnormal relationships between rCBF and speech rate found in PD by introducing a left IFG subregion that increases with speech rate, but the conflicting left IFG subregion response remained. Conflicting IFG responses may account for some of the speech problems observed after STN-DBS. Cortical and subcortical regions may be differentially affected by STN-DBS.